Molecular Neurodegeneration,
Journal Year:
2022,
Volume and Issue:
17(1)
Published: March 21, 2022
Across
neurodegenerative
diseases,
common
mechanisms
may
reveal
novel
therapeutic
targets
based
on
neuronal
protection,
repair,
or
regeneration,
independent
of
etiology
site
disease
pathology.
To
address
these
and
discuss
emerging
treatments,
in
April,
2021,
Glaucoma
Research
Foundation,
BrightFocus
the
Melza
M.
Frank
Theodore
Barr
Foundation
collaborated
to
bring
together
key
opinion
leaders
experts
field
for
a
virtual
meeting
titled
"Solving
Neurodegeneration".
This
"think-tank"
style
focused
uncovering
mechanistic
roots
promising
new
catalyzed
by
goal
finding
treatments
glaucoma,
world's
leading
cause
irreversible
blindness
interest
three
hosting
foundations.
Glaucoma,
which
causes
vision
loss
through
degeneration
optic
nerve,
likely
shares
early
cellular
molecular
events
with
other
diseases
central
nervous
system.
Here
we
major
areas
overlap
between
system:
neuroinflammation,
bioenergetics
metabolism,
genetic
contributions,
neurovascular
interactions.
We
summarize
important
discussion
points
emphasis
research
that
are
most
innovative
treatment
neurodegeneration
yet
require
further
development.
The
is
highlighted
provides
unique
opportunities
collaboration
will
lead
efforts
preventing
ultimately
loss.
The Journal of Experimental Medicine,
Journal Year:
2020,
Volume and Issue:
217(4)
Published: March 25, 2020
The
blood
vessels
vascularizing
the
central
nervous
system
exhibit
a
series
of
distinct
properties
that
tightly
control
movement
ions,
molecules,
and
cells
between
parenchyma.
This
“blood–brain
barrier”
is
initiated
during
angiogenesis
via
signals
from
surrounding
neural
environment,
its
integrity
remains
vital
for
homeostasis
protection
throughout
life.
Blood–brain
barrier
dysfunction
contributes
to
pathology
in
range
neurological
conditions
including
multiple
sclerosis,
stroke,
epilepsy,
has
also
been
implicated
neurodegenerative
diseases
such
as
Alzheimer’s
disease.
review
will
discuss
current
knowledge
key
unanswered
questions
regarding
blood–brain
health
Signal Transduction and Targeted Therapy,
Journal Year:
2023,
Volume and Issue:
8(1)
Published: July 12, 2023
Abstract
Studies
in
neurodegenerative
diseases,
including
Alzheimer’s
disease,
Parkinson’s
disease
and
Amyotrophic
lateral
sclerosis,
Huntington’s
so
on,
have
suggested
that
inflammation
is
not
only
a
result
of
neurodegeneration
but
also
crucial
player
this
process.
Protein
aggregates
which
are
very
common
pathological
phenomenon
can
induce
neuroinflammation
further
aggravates
protein
aggregation
neurodegeneration.
Actually,
even
happens
earlier
than
aggregation.
Neuroinflammation
induced
by
genetic
variations
CNS
cells
or
peripheral
immune
may
deposition
some
susceptible
population.
Numerous
signaling
pathways
range
been
to
be
involved
the
pathogenesis
neurodegeneration,
although
they
still
far
from
being
completely
understood.
Due
limited
success
traditional
treatment
methods,
blocking
enhancing
inflammatory
considered
promising
strategies
for
therapy
many
them
got
exciting
results
animal
models
clinical
trials.
Some
them,
few,
approved
FDA
usage.
Here
we
comprehensively
review
factors
affecting
major
pathogenicity
sclerosis.
We
summarize
current
strategies,
both
clinic,
diseases.
Current Neuropharmacology,
Journal Year:
2020,
Volume and Issue:
18(11), P. 1106 - 1125
Published: May 28, 2020
The
only
conclusive
way
to
diagnose
Alzheimer's
is
carry
out
brain
autopsy
of
the
patient's
tissue
and
ascertain
whether
subject
had
or
any
other
form
dementia.
However,
due
non-feasibility
such
methods,
conclude
conditions,
medical
practitioners
use
tests
that
examine
a
mental
ability.Accurate
diagnosis
at
an
early
stage
need
hour
for
initiation
therapy.
cause
most
cases
still
remains
unknown
except
where
genetic
distinctions
have
been
observed.
Thus,
standard
drug
regimen
ensues
in
every
patient,
irrespective
cause,
which
may
not
always
be
beneficial
halting
reversing
disease
progression.
To
provide
better
life
patients
by
suppressing
existing
symptoms,
diagnosis,
curative
therapy,
site-specific
delivery
drugs,
application
hyphenated
methods
like
artificial
intelligence
brought
into
main
field
therapeutics.In
this
review,
we
compiled
hypotheses
explain
disease,
highlighted
gene
immunotherapy,
peptidomimetics,
metal
chelators,
probiotics
quantum
dots
as
advancements
strategies
manage
Alzheimer's.Biomarkers,
brain-imaging,
theranostics,
along
with
intelligence,
are
understood
future
management
Alzheimer's.
Molecules,
Journal Year:
2019,
Volume and Issue:
24(16), P. 2997 - 2997
Published: Aug. 19, 2019
Apitherapy
is
an
alternate
therapy
that
relies
on
the
usage
of
honeybee
products,
most
importantly
bee
venom
for
treatment
many
human
diseases.
The
can
be
introduced
into
body
by
manual
injection
or
direct
stings.
Bee
contains
several
active
molecules
such
as
peptides
and
enzymes
have
advantageous
potential
in
treating
inflammation
central
nervous
system
diseases,
Parkinson’s
disease,
Alzheimer’s
amyotrophic
lateral
sclerosis.
Moreover,
has
shown
promising
benefits
against
different
types
cancer
well
anti-viral
activity,
even
challenging
immunodeficiency
virus
(HIV).
Many
studies
described
biological
activities
components
launched
preclinical
trials
to
improve
use
apitoxin
its
constituents
next
generation
drugs.
aim
this
review
summarize
main
compounds
venom,
their
primary
properties,
mechanisms
action,
therapeutic
values
alternative
strategies.
